Evolution of Treatments for Hereditary Angioedema in Italy: Use of Lanadelumab in Clinical Practice <p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d10778704e83">Introduction: Hereditary angioedema (HEA) is a rare genetic disorder characterised by re...

'Evolution of Treatments for Hereditary Angioedema in Italy: Use of Lanadelumab in Clinical Practice' - an @aboutscience.bsky.social publication on #ScienceOpen:

🔎 www.scienceopen.com/document?vid...

🖇️ #HereditaryAngioedema #Lanadelumab #RareDiseases #ClinicalPharmacology #ItalyHealthcare

New Subcutaneous Administration for TAKHZYRO® Approved by EMA for HAE Patients The European Medicines Agency has approved a new subcutaneous dosage option for TAKHZYRO®, enhancing treatment for hereditary angioedema patients aged 12 and above.

New Subcutaneous Administration for TAKHZYRO® Approved by EMA for HAE Patients #None #Takeda #TAKHZYRO #lanadelumab

European Medicines Agency Approves New Subcutaneous Delivery Option for TAKHZYRO® The EMA has greenlighted a new subcutaneous option for TAKHZYRO® aimed at adolescents and adults, enhancing treatment accessibility for hereditary angioedema patients.

European Medicines Agency Approves New Subcutaneous Delivery Option for TAKHZYRO® #Spain #Zurich #Takeda #TAKHZYRO #lanadelumab

European Medicines Agency Approves New TAKHZYRO® Delivery Option for HAE Patients The EMA has approved an additional subcutaneous delivery option for TAKHZYRO®, enhancing treatment for HAE patients aged 12 and older. This innovation aims to improve patient quality of life.

European Medicines Agency Approves New TAKHZYRO® Delivery Option for HAE Patients #Germany #Zurich #HAE #TAKHZYRO #lanadelumab

European Medicines Agency Approves New Administration Route for TAKHZYRO® in HAE Patients TAKEDA’s TAKHZYRO® (lanadelumab) gains EMA approval for a new subcutaneous pen option for HAE patients aged 12 and older, enhancing treatment accessibility.

European Medicines Agency Approves New Administration Route for TAKHZYRO® in HAE Patients #None #Takeda #TAKHZYRO #lanadelumab